Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
NIVOLUMAB-RELATLIMAB-RMBW 240-80 MG/20ML IV SOLN (CDM RX-148667) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved June 26, 2026 , from http://ppman.hank.ai/transparency/procedure/RX-148667/by-state?code_type=CDM
“NIVOLUMAB-RELATLIMAB-RMBW 240-80 MG/20ML IV SOLN (CDM RX-148667) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/RX-148667/by-state?code_type=CDM. Accessed
June 26, 2026 .
“NIVOLUMAB-RELATLIMAB-RMBW 240-80 MG/20ML IV SOLN (CDM RX-148667) by State,” HANK Price Transparency ,
accessed June 26, 2026 ,
http://ppman.hank.ai/transparency/procedure/RX-148667/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
RX-148667 — Nivolumab-relatlimab-rmbw 240-80 Mg/20ml IV Soln
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$39,542
National median
$39,542 – $39,542
IQR (p25 – p75)
2
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for RX-148667 (CDM), with interquartile range
State Median p25 p75
IL $39,542 $39,542 $39,542